RhumbLine Advisers
CKPT

RhumbLine Advisers’s Checkpoint Therapeutics CKPT Stock Holding History

RhumbLine Advisers’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,820
Closed -$89K – 3011
2021
Q1 		$89K Sell
2,820
-241
-8% -$8.08K ﹤0.01% 2945
2020
Q4 		$81K Buy
3,061
+500
+20% +$12.7K ﹤0.01% 2988
2020
Q3 		$69K Sell
2,561
-678
-21% -$16.3K ﹤0.01% 2928
2020
Q2 		$64K Buy
3,239
+1,538
+90% +$28K ﹤0.01% 3013
2020
Q1 		$26K Hold
1,701
– – ﹤0.01% 2896
2019
Q4 		$29K Hold
1,701
– – ﹤0.01% 2933
2019
Q3 		$42K Buy
1,701
+15
+0.9% +$412 ﹤0.01% 2931
2019
Q2 		$51K Buy
+1,686
New +$66.2K ﹤0.01% 2955

Other funds holding CKPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SAG
Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

RhumbLine Advisers's CKPT Position: Q2 2021 in Review

RhumbLine Advisers sold out of Checkpoint Therapeutics (CKPT) in Q2 2021, closing a stake of 2,820 shares — an estimated $89K sold.

RhumbLine Advisers first reported a position in CKPT in Q2 2019 and held it in 8 quarters. The position peaked at $89K in Q1 2021. 69 funds tracked by Wall St. Rank hold CKPT as of Q2 2021.

  • RhumbLine Advisers reported no remaining Checkpoint Therapeutics position as of Q2 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 2,820 Checkpoint Therapeutics shares in Q2 2021, an estimated $89K.
  • RhumbLine Advisers first reported a position in Checkpoint Therapeutics in Q2 2019 and held it in 8 quarters.
  • RhumbLine Advisers's Checkpoint Therapeutics position peaked at $89K in Q1 2021.
  • 69 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.